Cargando…
Isocitrate dehydrogenase 1 mutation subtypes at site 132 and their translational potential in glioma
In recent years, de novo missense structural mutations in the IDH1 gene of arginine at site 132 (R132) have become a standard for diagnostication and prognostication in glioma management. As our clinical understanding of this mutation grows, so too does the number of mutation subtypes reported in th...
Autores principales: | Lu, Victor M, McDonald, Kerrie L |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Future Medicine Ltd
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6001689/ https://www.ncbi.nlm.nih.gov/pubmed/29303363 http://dx.doi.org/10.2217/cns-2017-0019 |
Ejemplares similares
-
Screening of Methylation Signature and Gene Functions Associated With the Subtypes of Isocitrate Dehydrogenase-Mutation Gliomas
por: Pan, XiaoYong, et al.
Publicado: (2019) -
Ivosidenib in Isocitrate Dehydrogenase 1–Mutated Advanced Glioma
por: Mellinghoff, Ingo K., et al.
Publicado: (2020) -
Isocitrate dehydrogenase mutations: new opportunities for translational research
por: Keum, Young-Sam, et al.
Publicado: (2015) -
Isocitrate Dehydrogenase Mutations in Glioma: Genetics, Biochemistry, and Clinical Indications
por: Liu, Yang, et al.
Publicado: (2020) -
EGFRvIII expression and isocitrate dehydrogenase mutations in patients with glioma
por: Taher, Mohiuddin M., et al.
Publicado: (2020)